Endocrine Abstracts

Aim: To study the effect of testosterone replacement treatment in the aging male with T2DM.

Material and methods: Twenty-six hypogonadal men with T2DM and late-onset hypogonadism (Total testosterone at diagnosis <12 nmol/l) between the age 50–65 years (55.00 (50.00;58.00)) were treated with a 1% testosterone gel (AndroGel) (5 g/day) within 6 months. Patients were assessed before the first using of AndroGel, in one week interval and in 6 months. At each consultation laboratory results, quality of life, mood, sexual function and skin reactions were monitored. Data are presented as mean±S.D. or median (25th–75th percentile).

Results: Testosterone levels increased from 4.65 (2.70;6.10) nmol/l at baseline to 13.65 (12.60;15.20) nmol/l after 24 weeks of treatment (P<0.001). Free testosterone increased from 0.106 (0.062;0.152) nmol/l to 0.426 (0.345;0.553) nmol/l (P<0.001). SHBG decreased from 43.75 (31.83;48.48) nmol/l to 30.40 (26.28;32.03) nmol/l (P<0.001). We showed reduction of levels of TG from 2.09 (1.37;3.42) mmol/l to 1.33 (1.12;1.62) mmol/l (P=0.002), HbA1C from 8 (6.93;10.68)% to 6.8 (5.90;8.15)% (p<0.05), leptin from 10.0 (4.0;22.7) μg/l to 5.25 (4.03;8.23) μg/l, HOMA-IR from 4.37 (1.98;5.76) to 2.46 (1.98;3.04).

PSA levels fluctuated minimally within in the normal range. All patients reported improved mood, sexual function and quality of life.

Conclusions: Treatment with the 1% testosterone gel (AndroGel) was associated with significant improvements in the testosterone, triglyceride, HbA1C, leptin, HOMA-IR levels in men with late-onset hypogonadism and T2DM.